These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 28672102)

  • 41. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
    Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
    Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Next generation sequencing-based expression profiling identifies signatures from benign stromal proliferations that define stromal components of breast cancer.
    Guo X; Zhu SX; Brunner AL; van de Rijn M; West RB
    Breast Cancer Res; 2013 Dec; 15(6):R117. PubMed ID: 24342436
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Separation of breast cancer and organ microenvironment transcriptomes in metastases.
    Alzubi MA; Turner TH; Olex AL; Sohal SS; Tobin NP; Recio SG; Bergh J; Hatschek T; Parker JS; Sartorius CA; Perou CM; Dozmorov MG; Harrell JC
    Breast Cancer Res; 2019 Mar; 21(1):36. PubMed ID: 30841919
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis.
    Del Casar JM; Martín A; García C; Corte MD; Alvarez A; Junquera S; González LO; Bongera M; García-Muñiz JL; Allende MT; Vizoso F
    Eur J Obstet Gynecol Reprod Biol; 2008 Dec; 141(2):147-52. PubMed ID: 18768247
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A genomic ruler to assess oncogenic transition between breast tumor and stroma.
    Dhage S; Ernlund A; Ruggles K; Axelrod D; Berman R; Roses D; Schneider RJ
    PLoS One; 2018; 13(10):e0205602. PubMed ID: 30325954
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Podoplanin increases the migration of human fibroblasts and affects the endothelial cell network formation: A possible role for cancer-associated fibroblasts in breast cancer progression.
    Suchanski J; Tejchman A; Zacharski M; Piotrowska A; Grzegrzolka J; Chodaczek G; Nowinska K; Rys J; Dziegiel P; Kieda C; Ugorski M
    PLoS One; 2017; 12(9):e0184970. PubMed ID: 28938000
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer.
    Brodsky AS; Xiong J; Yang D; Schorl C; Fenton MA; Graves TA; Sikov WM; Resnick MB; Wang Y
    BMC Cancer; 2016 Apr; 16():274. PubMed ID: 27090210
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype.
    Cheng Q; Chang JT; Gwin WR; Zhu J; Ambs S; Geradts J; Lyerly HK
    Breast Cancer Res; 2014 Jul; 16(4):407. PubMed ID: 25060555
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
    De Brot M; Rocha RM; Soares FA; Gobbi H
    Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
    Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
    Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Action of Discoidin Domain Receptor 2 in Basal Tumor Cells and Stromal Cancer-Associated Fibroblasts Is Critical for Breast Cancer Metastasis.
    Corsa CA; Brenot A; Grither WR; Van Hove S; Loza AJ; Zhang K; Ponik SM; Liu Y; DeNardo DG; Eliceiri KW; Keely PJ; Longmore GD
    Cell Rep; 2016 Jun; 15(11):2510-23. PubMed ID: 27264173
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.
    Lehmann BD; Ding Y; Viox DJ; Jiang M; Zheng Y; Liao W; Chen X; Xiang W; Yi Y
    BMC Cancer; 2015 Mar; 15():179. PubMed ID: 25886164
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CHEK2 represses breast stromal fibroblasts and their paracrine tumor-promoting effects through suppressing SDF-1 and IL-6.
    Al-Rakan MA; Hendrayani SF; Aboussekhra A
    BMC Cancer; 2016 Aug; 16():575. PubMed ID: 27484185
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Subtype-specific prognostic impact of different immune signatures in node-negative breast cancer.
    Heimes AS; Madjar K; Edlund K; Battista MJ; Almstedt K; Elger T; Krajnak S; Rahnenführer J; Brenner W; Hasenburg A; Hengstler JG; Schmidt M
    Breast Cancer Res Treat; 2017 Sep; 165(2):293-300. PubMed ID: 28585074
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tumor-Associated Stromal Cellular Density as a Predictor of Recurrence and Mortality in Breast Cancer: Results from Ethnically Diverse Study Populations.
    Abubakar M; Zhang J; Ahearn TU; Koka H; Guo C; Lawrence SM; Mutreja K; Figueroa JD; Ying J; Lissowska J; Lyu N; Garcia-Closas M; Yang XR
    Cancer Epidemiol Biomarkers Prev; 2021 Jul; 30(7):1397-1407. PubMed ID: 33952648
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cancer Cell Intrinsic and Immunologic Phenotypes Determine Clinical Outcomes in Basal-like Breast Cancer.
    Li CI; Zhang Y; Cieślik M; Wu YM; Xiao L; Cobain E; Tang MC; Cao X; Porter P; Guenthoer J; Robinson DR; Chinnaiyan AM
    Clin Cancer Res; 2021 Jun; 27(11):3079-3093. PubMed ID: 33753452
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Human Organotypic Microfluidic Tumor Model Permits Investigation of the Interplay between Patient-Derived Fibroblasts and Breast Cancer Cells.
    Truong DD; Kratz A; Park JG; Barrientos ES; Saini H; Nguyen T; Pockaj B; Mouneimne G; LaBaer J; Nikkhah M
    Cancer Res; 2019 Jun; 79(12):3139-3151. PubMed ID: 30992322
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Factors Associated with the Use of Gene Expression Profiles in Estrogen Receptor-Positive Early-Stage Breast Cancer Patients: A Nationwide Study.
    Kuijer A; Schreuder K; Elias SG; Smorenburg CH; Rutgers EJ; Siesling S; van Dalen T
    Public Health Genomics; 2016; 19(5):276-81. PubMed ID: 27508402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.